Humira has announced that the patent litigation was resolved between AbbVie and Boehringer Ingelheim. Based on the resolution, AbbVie will provide a non-exclusive license to BI in the United States.
Biosimilar Cyltezo will be available from July 1, 2023. BI will pay royalties for AbbVie. Earlier AbbVie has sued the BI for infringing more than 70 patents in 2017 during the development of adalimumab biosimilar.
BI follows in the line of Coherus, Pfizer, Amgen, Mylan, Samsung Bioepis, Sandoz, Fresenius Kabi, and Momenta which got the rights for adalimumab biosimilar.
Amgen’s product Amjevita will be the first biosimilar that will be available in the United States market. It will be available from January 2023